Sickle Cell Matters

September, Sickle Cell Awareness Month

Sickle cell disease (SCD) is one of the most common inherited blood disorders worldwide. The global prevalence of SCD has been reported to be 112 per 100,000 live births, with the highest birth prevalence being in Africa – 1,125 per 100,000 births compared with 43 per 100,000 births in Europe1. As an autosomal recessive disorder, a child with SCD is born to two parents who are asymptomatic carriers of a sickle cell mutation (genetic change). The hallmark trait of the disease is the crescent moon shape of the red blood cells (RBCs), also known as ‘sickle’, which gives the disease its name.

The rigid shape of the RBCs is due to abnormal hemoglobin. Hemoglobin is a protein carried by the RBCs whose function is to transport oxygen throughout the body. Hemoglobin also carries iron – whose interaction with oxygen is the cause of the red color of the RBCs. Hemoglobin is made up of 2 α-protein and 2 β-protein subunits that is expressed by the HBB gene. When mutations occur in the HBB gene, hemoglobin’s function is altered. The different forms and varying severity of SCD depend on the mutation and whether one or both of β-globin chains are affected.

The complications of SCD are caused by the abnormal shape of RBCs. Normally, RBCs are round and flexible, able to move easily through the blood vessels and deliver oxygen and nutrients to the body. The sickled RBCs are misshapen and sticky. Their shape causes them to get stuck in small blood vessels, restricting the flow of other cells and slowing or blocking the transport of oxygen to the body – causing anemia. This causes painful episodes, termed ‘crises’, which deprive tissues and organs of oxygen and nutrients and can overtime lead to organ damage2,3. The intensity and the length of these crises varies. Some patients suffer from chronic pain due to bone and joint damage caused by the disease. The organs that are most affected are the lungs, kidneys, spleen and brain. If RBCs get stuck to the tiny blood vessels that supply the eyes, they could damage the retina leading to vision problems2,3. The blockage of blood vessels by sickled RBCs can also cause stroke, pulmonary hypotension, heart failure and even death2,3,4. Individuals with RBC are also in danger of frequent and severe infections, as the organs that help fight infections – like the spleen – are damaged and may need to be removed. Sickled cells break apart easily and die faster than healthy RBCs. Instead of the normal lifespan of 120 days, sickled RBCs only live 10-20 days3. Shortage of RBCs can cause acute chest syndrome due to low oxygen levels, and delay growth during puberty.

The only cure for SCD is a bone marrow transplant, which is a very risky procedure that is only available to people under 16 years of age due to the many complications, including death. Current treatment focuses at avoiding crises, reducing pain, relieving symptoms and preventing complications caused by the disease. Patients with SCD receive frequent blood transfusions where only the RBCs are donated to increase the number of healthy RBCs in their circulation. Iron chelation therapy may be needed to reduce the iron buildup from the blood transfusions as it is hurtful for the heart, liver and other organs. Antibiotics like penicillin can help fight infections and are especially important when the spleen has been removed. Hydroxyurea, a medication also used in cervical cancer and leukemia, can stimulate fetal hemoglobin production which prevents formation of sickle cells. It may reduce the frequency of painful crises or the need for frequent blood transfusions, but it could increase infection risk3. Experimental treatments like gene therapy, nitric oxide gas to help keep the blood vessels open and drugs to boost fetal hemoglobin are being examined. People with SCD can benefit from having a healthy diet, taking folic acid supplements which help the bone marrow make new RBCs, drinking plenty of water, avoiding temperature extremes and exercising regularly – without overdoing it. Carriers of sickle cell – sickle cell trait – rarely have any complications of SCD, but they may be more likely to experience heat stroke and muscle breakdown when doing intensive exercise.

Approximately 5% of the world’s population is a carrier of hemoglobinopathies, which include SCD and thalassemia5. Due to the high frequency and severity of SCD, many countries like the Unites States of America, United Kingdom, France, the Netherlands, Spain and Malta have national newborn screening programs to detect the disease early through a simple blood test6. SCD is also included in many carrier screening panels so that couples or individuals can get informed on their genetic status and reproductive options. Non-invasive prenatal testing (NIPT) for SCD is also available, with subsequent invasive procedures like chorionic villus sampling (CVS) or amniocentesis recommended to confirm disease presence in case of a positive NIPT result. Early diagnosis and treatment of SCD is important for the prevention of SCD-related complications.

Today, the vast majority of SCD patients live well into adulthood in developed countries. In resource-poor countries, over 90% of children with SCD do not survive past childhood.7 Globally, a 30% growth in the number of people with SCD is expected by 20507. Education, support and awareness on SCD can be effective tools in reducing mortality and promoting the finding of a cure.

VERAgene NIPT, offered by NIPD Genetics, can detect sickle cell disease, along with 49 other monogenic disorders, 8 chromosomal aneuploidies and 4 microdeletions from the 10th week of pregnancy. To learn more please visit NIPT results, possible next steps and clinical management should always be fully discussed with your healthcare provider.


  1. Wastnedge E. et al. (2018), ‘The global burden of sickle cell disease in children under 5 years of age: a systematic review and meta-analysis’. Journal of global health; 8(2): 021103
  2. American Society of Hematology (2019),
  3. Mayo Clinic (1998-2019),
  4. Genetics Home Reference (2019),
  5. World Health Organization, Regional Office for Africa (2015),
  6. Daniel Y. et al. (2019), ‘Newborn Screening for Sickle Cell Disease in Europe’. International Journal of Neonatal Screening, 5,15
  7. Sickle Cell Disease Coalition, Understanding the Impact of Sickle Cell Disease Infographic (2017),

View All Posts

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer. will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.


We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact

Ok got it!